{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T20:37:13Z","timestamp":1788381433252,"version":"build-2803163510"},"reference-count":48,"publisher":"American Academy of Pediatrics (AAP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,1]]},"abstract":"<jats:sec>\n                  <jats:title>BACKGROUND AND OBJECTIVES<\/jats:title>\n                  <jats:p>The messenger RNA (mRNA)-based coronavirus disease 2019 vaccines approved for use in children &amp;lt;5 years of age have different antigen doses and administration schedules that could affect vaccine immunogenicity and effectiveness. We sought to compare the strength and breadth of serum binding and neutralizing antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) elicited by monovalent mRNA-based coronavirus disease 2019 vaccines in young children.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS<\/jats:title>\n                  <jats:p>We conducted a prospective cohort study of children 6 months to 4 years of age who completed primary series vaccination with monovalent mRNA-1273 or BNT162b2 vaccines. Serum was collected 1 month after primary vaccine series completion for the measurement of SARS-CoV-2-specific humoral immune responses, including antibody binding responses to Spike proteins from an ancestral strain (D614G) and major variants of SARS-CoV-2 and antibody neutralizing activity against D614G and Omicron\u00a0subvariants (BA.1, BA.4\/5).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Of 75 participants, 40 (53%) received mRNA-1273 and 35 (47%) received BNT162b2. Children receiving either primary vaccine series developed robust and broad SARS-CoV-2-specific binding and neutralizing antibodies, including to Omicron\u00a0subvariants. Children with a previous history of SARS-CoV-2 infection developed significantly higher antibody binding responses and neutralization titers to Omicron\u00a0subvariants, which is consistent with the occurrence of identified infections during the circulation of Omicron\u00a0subvariants in the region.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Monovalent mRNA-1273 and BNT162b2 elicited similar antibody responses 1 month after vaccination in young children. In addition, previous infection significantly enhanced the strength of antibody responses to Omicron\u00a0subvariants. The authors of future studies should evaluate incorporation of these vaccines into the standard childhood immunization schedule.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1542\/peds.2024-066190","type":"journal-article","created":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T04:01:07Z","timestamp":1711684867000},"source":"Crossref","is-referenced-by-count":7,"title":["Immunogenicity of Monovalent mRNA-1273 and BNT162b2 Vaccines in Children &amp;lt;5 Years of Age"],"prefix":"10.1542","volume":"153","author":[{"given":"Trisha","family":"Dalapati","sequence":"first","affiliation":[{"name":"aMedical Scientist Training Program"},{"name":"bDepartment of Molecular Genetics and Microbiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin A.","family":"Williams","sequence":"additional","affiliation":[{"name":"hWeill Cornell Medicine, Department of Pediatrics, Division of Infectious Diseases, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena E.","family":"Giorgi","sequence":"additional","affiliation":[{"name":"cDepartment of Pediatrics, Division of Pediatric Critical Care Medicine"},{"name":"iFred Hutchinson Cancer Center, Vaccine and Infectious Disease Division, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jillian H.","family":"Hurst","sequence":"additional","affiliation":[{"name":"dDepartment of Pediatrics, Division of Infectious Diseases"},{"name":"eDepartment of Pediatrics, Children\u2019s Health & Discovery Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savannah","family":"Herbek","sequence":"additional","affiliation":[{"name":"hWeill Cornell Medicine, Department of Pediatrics, Division of Infectious Diseases, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jui-Lin","family":"Chen","sequence":"additional","affiliation":[{"name":"hWeill Cornell Medicine, Department of Pediatrics, Division of Infectious Diseases, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Kosman","sequence":"additional","affiliation":[{"name":"hWeill Cornell Medicine, Department of Pediatrics, Division of Infectious Diseases, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre T.","family":"Rotta","sequence":"additional","affiliation":[{"name":"cDepartment of Pediatrics, Division of Pediatric Critical Care Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas A.","family":"Turner","sequence":"additional","affiliation":[{"name":"fDepartment of Medicine, Division of Infectious Diseases"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Pulido","sequence":"additional","affiliation":[{"name":"dDepartment of Pediatrics, Division of Infectious Diseases"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jhoanna N.","family":"Aquino","sequence":"additional","affiliation":[{"name":"dDepartment of Pediatrics, Division of Infectious Diseases"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor S.","family":"Pfeiffer","sequence":"additional","affiliation":[{"name":"dDepartment of Pediatrics, Division of Infectious Diseases"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"gDepartment of Pediatrics, Children\u2019s Clinical Research Unit, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevieve G.","family":"Fouda","sequence":"additional","affiliation":[{"name":"hWeill Cornell Medicine, Department of Pediatrics, Division of Infectious Diseases, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sallie R.","family":"Permar","sequence":"additional","affiliation":[{"name":"hWeill Cornell Medicine, Department of Pediatrics, Division of Infectious Diseases, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Kelly","sequence":"additional","affiliation":[{"name":"bDepartment of Molecular Genetics and Microbiology"},{"name":"dDepartment of Pediatrics, Division of Infectious Diseases"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2024,5,17]]},"reference":[{"key":"2024060102542198200_B1","article-title":"COVID data tracker: demographic trends of COVID-19 cases and deaths in the US reported to CDC","author":"Centers for Disease Control and Prevention"},{"key":"2024060102542198200_B2","article-title":"Coronavirus (COVID-19) update: FDA authorizes Moderna and Pfizer-BioNTech COVID-19 vaccines for children down to 6 months of age","author":"U.S. Food and Drug Administration"},{"key":"2024060102542198200_B3","article-title":"Moderna COVID-19 vaccine: at-a-glance","author":"Centers for Disease Control and Prevention"},{"issue":"18","key":"2024060102542198200_B4","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa2209367","article-title":"Evaluation of mRNA-1273 vaccine in children 6 months to 5 years of age","volume":"387","author":"Anderson","year":"2022","journal-title":"N Engl J Med"},{"key":"2024060102542198200_B5","article-title":"Pfizer-BioNTech COVID-19 vaccine: at-a-glance","author":"Centers for Disease Control and Prevention"},{"issue":"7","key":"2024060102542198200_B6","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa2211031","article-title":"Evaluation of BNT162b2 Covid-19 vaccine in children younger than 5 years of age","volume":"388","author":"Mu\u00f1oz","year":"2023","journal-title":"N Engl J Med"},{"key":"2024060102542198200_B7","article-title":"Coronavirus (COVID-19) update: FDA authorizes changes to simplify use of bivalent mRNA COVID-19 vaccines","author":"U.S. Food and Drug Administration"},{"key":"2024060102542198200_B8","article-title":"Coronavirus (COVID-19) update: FDA authorizes updated (bivalent) COVID-19 vaccines for children down to 6 months of age","author":"U.S. Food and Drug Administration"},{"key":"2024060102542198200_B9","article-title":"FDA takes action on updated mRNA COVID-19 vaccines to better protect against currently circulating variants","author":"U.S. Food and Drug Administration"},{"issue":"38","key":"2024060102542198200_B10","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.15585\/mmwr.mm7038e1","article-title":"Comparative effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) vaccines in preventing COVID-19 hospitalizations among adults without ummunocompromising conditions - United States, March-August 2021","volume":"70","author":"Self","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"20","key":"2024060102542198200_B11","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1001\/jama.2021.19499","article-title":"Association between mRNA vaccination and COVID-19 hospitalization and disease severity","volume":"326","author":"Tenforde","year":"2021","journal-title":"JAMA"},{"issue":"2","key":"2024060102542198200_B12","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1056\/NEJMoa2115463","article-title":"Comparative effectiveness of BNT162b2 and mRNA-1273 vaccines in U.S. veterans","volume":"386","author":"Dickerman","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"2024060102542198200_B13","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.medj.2021.12.002","article-title":"Comparative effectiveness of mRNA-1273 and BNT162b2 against symptomatic SARS-CoV-2 infection","volume":"3","author":"Puranik","year":"2022","journal-title":"Med"},{"issue":"7","key":"2024060102542198200_B14","doi-asserted-by":"crossref","first-page":"177","DOI":"10.15585\/mmwr.mm7207a3","article-title":"Preliminary estimates of effectiveness of monovalent mRNA vaccines in preventing symptomatic SARS-CoV-2 infection among children aged 3-5 years - Increasing Community Access to Testing Program, United States, July 2022-February 2023","volume":"72","author":"Fleming-Dutra","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"33","key":"2024060102542198200_B15","doi-asserted-by":"crossref","first-page":"886","DOI":"10.15585\/mmwr.mm7233a2","article-title":"Effectiveness of monovalent and bivalent mRNA vaccines in preventing COVID-19-associated emergency department and urgent care encounters among children aged 6 months-5 years - VISION Network, United States, July 2022-June 2023","volume":"72","author":"Link-Gelles","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"17","key":"2024060102542198200_B16","doi-asserted-by":"crossref","first-page":"e150909","DOI":"10.1172\/jci.insight.150909","article-title":"Asymptomatic or mild symptomatic SARS-CoV-2 infection elicits durable neutralizing antibody responses in children and adolescents","volume":"6","author":"Garrido","year":"2021","journal-title":"JCI Insight"},{"issue":"9","key":"2024060102542198200_B17","doi-asserted-by":"crossref","first-page":"e2875","DOI":"10.1093\/cid\/ciaa1693","article-title":"Severe acute respiratory syndrome coronavirus 2 infections among children in the Biospecimens from Respiratory Virus-Exposed Kids (BRAVE Kids) study","volume":"73","author":"Hurst","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"60","key":"2024060102542198200_B18","doi-asserted-by":"crossref","first-page":"eabj3684","DOI":"10.1126\/sciimmunol.abj3684","article-title":"SARS-CoV-2 vaccines elicit durable immune responses in infant rhesus macaques","volume":"6","author":"Garrido","year":"2021","journal-title":"Sci Immunol"},{"key":"2024060102542198200_B19","article-title":"R: A language and environment for statistical computing","author":"R Foundation for Statistical Computing"},{"issue":"1","key":"2024060102542198200_B20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v067.i01","article-title":"Fitting linear mixed-effects models using lme4","volume":"67","author":"Bates","year":"2015","journal-title":"J Stat Softw"},{"issue":"11","key":"2024060102542198200_B21","first-page":"1","article-title":"corrplot: Visualization of a correlation matrix","volume":"230","author":"Wei","year":"2013","journal-title":"R package version 0.73"},{"issue":"4","key":"2024060102542198200_B22","first-page":"1","article-title":"beeswarm: the bee swarm plot, an alternative to stripchart","volume":"3","author":"Eklund","year":"2016","journal-title":"R package version 0.2"},{"key":"2024060102542198200_B23","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-24277-4","volume-title":"ggplot2: Elegant Graphics for Data Analysis","author":"Wickham","year":"2016"},{"key":"2024060102542198200_B24","doi-asserted-by":"crossref","first-page":"994160","DOI":"10.3389\/fmed.2022.994160","article-title":"Comparison of vaccine-induced antibody neutralization against SARS-CoV-2 variants of concern following primary and booster doses of COVID-19 vaccines","volume":"9","author":"Hvidt","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"2024060102542198200_B25","doi-asserted-by":"crossref","first-page":"e827","DOI":"10.1093\/cid\/ciab1038","article-title":"Neutralizing antibody response to pseudotype severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) differs between mRNA-1273 and BNT162b2 coronavirus disease 2019 (COVID-19) vaccines and by history of SARS-CoV-2 infection","volume":"75","author":"Tyner","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"15","key":"2024060102542198200_B26","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1001\/jama.2021.15125","article-title":"Comparison of SARS-CoV-2 antibody response following vaccination with BNT162b2 and mRNA-1273","volume":"326","author":"Steensels","year":"2021","journal-title":"JAMA"},{"issue":"5","key":"2024060102542198200_B27","doi-asserted-by":"crossref","first-page":"101048","DOI":"10.1016\/j.xcrm.2023.101048","article-title":"Hybrid immunity expands the functional humoral footprint of both mRNA and vector-based SARS-CoV-2 vaccines","volume":"4","author":"Kaplonek","year":"2023","journal-title":"Cell Rep Med"},{"issue":"6549","key":"2024060102542198200_B28","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1126\/science.abg9175","article-title":"mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection","volume":"372","author":"Stamatatos","year":"2021","journal-title":"Science"},{"issue":"12","key":"2024060102542198200_B29","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1038\/s41591-021-01548-7","article-title":"Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK","volume":"27","author":"Pouwels","year":"2021","journal-title":"Nat Med"},{"issue":"68","key":"2024060102542198200_B30","doi-asserted-by":"crossref","first-page":"eabn8014","DOI":"10.1126\/sciimmunol.abn8014","article-title":"Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants","volume":"7","author":"Bates","year":"2022","journal-title":"Sci Immunol"},{"issue":"7867","key":"2024060102542198200_B31","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41586-021-03696-9","article-title":"Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection","volume":"595","author":"Wang","year":"2021","journal-title":"Nature"},{"issue":"6","key":"2024060102542198200_B32","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1473-3099(22)00143-8","article-title":"Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden","volume":"22","author":"Nordstr\u00f6m","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2024060102542198200_B33","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ijid.2023.05.005","article-title":"Neutralizing antibodies against Omicron BA.5 among children with infection alone, vaccination alone, and hybrid immunity","volume":"134","author":"Suntronwong","year":"2023","journal-title":"Int J Infect Dis"},{"issue":"7","key":"2024060102542198200_B34","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41579-021-00573-0","article-title":"SARS-CoV-2 variants, spike mutations and immune escape","volume":"19","author":"Harvey","year":"2021","journal-title":"Nat Rev Microbiol"},{"issue":"637","key":"2024060102542198200_B35","doi-asserted-by":"crossref","first-page":"eabn8057","DOI":"10.1126\/scitranslmed.abn8057","article-title":"Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection","volume":"14","author":"Evans","year":"2022","journal-title":"Sci Transl Med"},{"issue":"8","key":"2024060102542198200_B36","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/s41564-022-01143-7","article-title":"SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway","volume":"7","author":"Willett","year":"2022","journal-title":"Nat Microbiol"},{"issue":"1","key":"2024060102542198200_B37","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1056\/NEJMc2206576","article-title":"Neutralization escape by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4, and BA.5","volume":"387","author":"Hachmann","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"2024060102542198200_B38","doi-asserted-by":"crossref","first-page":"e2232760","DOI":"10.1001\/jamanetworkopen.2022.32760","article-title":"Estimated effectiveness of COVID-19 vaccines against Omicron or Delta symptomatic infection and severe outcomes","volume":"5","author":"Buchan","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2024060102542198200_B39","doi-asserted-by":"crossref","first-page":"103944","DOI":"10.1016\/j.ebiom.2022.103944","article-title":"Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies","volume":"78","author":"Tada","year":"2022","journal-title":"EBioMedicine"},{"issue":"1","key":"2024060102542198200_B40","doi-asserted-by":"crossref","first-page":"7952","DOI":"10.1038\/s41467-023-43152-y","article-title":"Neutralization of SARS-CoV-2 Omicron BQ.1, BQ.1.1 and XBB.1 variants following SARS-CoV-2 infection or vaccination in children","volume":"14","author":"Bellusci","year":"2023","journal-title":"Nat Commun"},{"issue":"11","key":"2024060102542198200_B41","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1056\/NEJMc2119912","article-title":"SARS-CoV-2 Omicron variant neutralization after mRNA-1273 booster vaccination","volume":"386","author":"Pajon","year":"2022","journal-title":"N Engl J Med"},{"issue":"6581","key":"2024060102542198200_B42","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1126\/science.abn7591","article-title":"Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera","volume":"375","author":"Muik","year":"2022","journal-title":"Science"},{"issue":"1","key":"2024060102542198200_B43","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/s41467-024-45181-7","article-title":"Humoral profiles of toddlers and young children following SARS-CoV-2 mRNA vaccination","volume":"15","author":"Nziza","year":"2024","journal-title":"Nat Commun"},{"key":"2024060102542198200_B44","first-page":"2023.07.31.23293337","article-title":"Differential host responses within the upper respiratory tract and peripheral blood of children and adults with SARS-CoV-2 infection","author":"Hurst","year":"2023","journal-title":"medRxiv"},{"issue":"9","key":"2024060102542198200_B45","doi-asserted-by":"crossref","first-page":"e148694","DOI":"10.1172\/jci.insight.148694","article-title":"Natural mucosal barriers and COVID-19 in children","volume":"6","author":"Pierce","year":"2021","journal-title":"JCI Insight"},{"key":"2024060102542198200_B46","doi-asserted-by":"crossref","first-page":"611337","DOI":"10.3389\/fimmu.2020.611337","article-title":"Mucosal immunity in COVID-19: a neglected but critical aspect of SARS-CoV-2 infection","volume":"11","author":"Russell","year":"2020","journal-title":"Front Immunol"},{"issue":"1","key":"2024060102542198200_B47","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3390\/vaccines10010064","article-title":"Large-scale study of antibody titer decay following BNT162b2 mRNA vaccine or SARS-CoV-2 infection","volume":"10","author":"Israel","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"11","key":"2024060102542198200_B48","doi-asserted-by":"crossref","first-page":"000678.v3","DOI":"10.1099\/acmi.0.000678.v3","article-title":"11-month SARS-CoV-2 immunogenicity decay, and associated factors, among mRNA vaccinees: implications for booster vaccination","volume":"5","author":"Asamoah-Boaheng","year":"2023","journal-title":"Access Microbiol"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2024-066190\/1659130\/peds.2024-066190.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2024-066190\/1659130\/peds.2024-066190.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T02:55:51Z","timestamp":1717210551000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/153\/6\/e2024066190\/196958\/Immunogenicity-of-Monovalent-mRNA-1273-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,17]]},"references-count":48,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,5,17]]},"published-print":{"date-parts":[[2024,6,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2024-066190","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,17]]},"article-number":"e2024066190"}}